Suppr超能文献

个人癌症病史和家族癌症病史对降低风险的输卵管卵巢切除术接受率的影响。

The effect of personal medical history and family history of cancer on the uptake of risk-reducing salpingo-oophorectomy.

作者信息

van der Aa Jessica E, Hoogendam Jacob P, Butter Els S F, Ausems Margreet G E M, Verheijen René H M, Zweemer Ronald P

机构信息

Department of Gynaecological Oncology, UMC Utrecht Cancer Center, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands.

Department of Medical Genetics, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands.

出版信息

Fam Cancer. 2015 Dec;14(4):539-44. doi: 10.1007/s10689-015-9827-7.

Abstract

Women with an increased lifetime risk of ovarian cancer are advised to undergo risk-reducing salpingo-oophorectomy (RRSO) to reduce risk of adnexal cancer. We investigated the uptake of RRSO and evaluated the influence of personal medical history of (breast) cancer, risk-reducing mastectomy (RRM) and family history of ovarian and/or breast cancer on the RRSO decision. This single center retrospective observational cohort study was performed in a tertiary multidisciplinary clinic for hereditary cancer of the University Medical Centre Utrecht, The Netherlands. Women ≥35 years old with an estimated lifetime risk of ovarian cancer ≥10%, who had completed childbearing, were eligible for RRSO. Uptake and timing of RRSO were analyzed. Influence of personal medical history and family history on RRSO decision making, were evaluated with logistic regression. The study population consisted of 218 women (45.0% BRCA1 mutation carrier, 28.0% BRCA2 mutation carrier, 27.0% with familial susceptibility) with 87.2% RRSO uptake. The median age at RRSO was 44.5 (range 28-73) years. Of the women undergoing RRSO, 78.3% needed ≤3 consultations to reach this decision. Multivariable analysis showed a significant difference in RRSO uptake for women with a history of RRM [OR 3.66 95% CI (1.12-11.98)], but no significant difference in women with a history of breast cancer [OR 1.38 95% CI (0.50-3.79)], nor with a family history of ovarian and/or breast cancer [OR 1.10 95% CI (0.44-2.76)]. We conclude that RRSO counseling, without the alternative of screening, is effective. The uptake is increased in women with a history of RRM.

摘要

建议卵巢癌终生风险增加的女性接受预防性输卵管卵巢切除术(RRSO)以降低附件癌风险。我们调查了RRSO的接受情况,并评估了(乳腺癌)个人病史、预防性乳房切除术(RRM)以及卵巢癌和/或乳腺癌家族史对RRSO决策的影响。这项单中心回顾性观察队列研究在荷兰乌得勒支大学医学中心的遗传性癌症三级多学科诊所进行。年龄≥35岁、估计卵巢癌终生风险≥10%且已完成生育的女性符合RRSO条件。分析了RRSO的接受情况和时间。通过逻辑回归评估个人病史和家族史对RRSO决策的影响。研究人群包括218名女性(45.0%为BRCA1突变携带者,28.0%为BRCA2突变携带者,27.0%有家族易感性),RRSO接受率为87.2%。RRSO的中位年龄为44.5岁(范围28 - 73岁)。在接受RRSO的女性中,78.3%在做出该决定前需要≤3次咨询。多变量分析显示,有RRM病史的女性在RRSO接受率上有显著差异[比值比(OR)3.66,95%置信区间(CI)(1.12 - 11.98)],但有乳腺癌病史的女性无显著差异[OR 1.38,95% CI(0.50 - 3.79)],有卵巢癌和/或乳腺癌家族史的女性也无显著差异[OR 1.10,95% CI(0.44 - 2.76)]。我们得出结论,在没有筛查替代方案的情况下,RRSO咨询是有效的。有RRM病史的女性接受率更高。

相似文献

3
Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers.
Breast Cancer Res Treat. 2014 Nov;148(2):397-406. doi: 10.1007/s10549-014-3134-0. Epub 2014 Oct 14.
5
Uptake of risk-reducing salpingo-oophorectomy among female BRCA mutation carriers: experience at the National Cancer Center of Korea.
J Cancer Res Clin Oncol. 2016 Jan;142(1):333-40. doi: 10.1007/s00432-015-2051-x. Epub 2015 Oct 5.
6
Cost-effectiveness of surveillance and prevention strategies in BRCA1/2 mutation carriers.
Breast Cancer. 2018 Mar;25(2):141-150. doi: 10.1007/s12282-017-0803-y. Epub 2017 Oct 10.
7
Risk-reducing surgery in BRCA1/BRCA2 mutation carriers: Are there factors associated with the choice?
Psychooncology. 2019 Sep;28(9):1871-1878. doi: 10.1002/pon.5166. Epub 2019 Jul 11.
10
Osteoporosis risk and management in BRCA1 and BRCA2 carriers who undergo risk-reducing salpingo-oophorectomy.
Gynecol Oncol. 2015 Sep;138(3):723-6. doi: 10.1016/j.ygyno.2015.06.020. Epub 2015 Jun 16.

引用本文的文献

4
Developing genetic counselling services in an underdeveloped healthcare setting.
J Community Genet. 2021 Oct;12(4):539-548. doi: 10.1007/s12687-021-00546-z. Epub 2021 Sep 20.

本文引用的文献

3
Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers.
Breast Cancer Res Treat. 2014 Nov;148(2):397-406. doi: 10.1007/s10549-014-3134-0. Epub 2014 Oct 14.
4
Risk management options elected by women after testing positive for a BRCA mutation.
Gynecol Oncol. 2014 Feb;132(2):428-33. doi: 10.1016/j.ygyno.2013.12.014. Epub 2013 Dec 16.
7
Impact of family history on choosing risk-reducing surgery among BRCA mutation carriers.
Am J Obstet Gynecol. 2013 Apr;208(4):329.e1-6. doi: 10.1016/j.ajog.2013.01.026. Epub 2013 Jan 17.
9
Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers.
Cancer Epidemiol Biomarkers Prev. 2012 Apr;21(4):645-57. doi: 10.1158/1055-9965.EPI-11-0888. Epub 2012 Feb 20.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验